JP2014523906A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523906A5
JP2014523906A5 JP2014519502A JP2014519502A JP2014523906A5 JP 2014523906 A5 JP2014523906 A5 JP 2014523906A5 JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014523906 A5 JP2014523906 A5 JP 2014523906A5
Authority
JP
Japan
Prior art keywords
administered
drug
defensins
agent
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519502A
Other languages
English (en)
Japanese (ja)
Other versions
JP6219277B2 (ja
JP2014523906A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063137 external-priority patent/WO2013007596A2/en
Publication of JP2014523906A publication Critical patent/JP2014523906A/ja
Publication of JP2014523906A5 publication Critical patent/JP2014523906A5/ja
Application granted granted Critical
Publication of JP6219277B2 publication Critical patent/JP6219277B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519502A 2011-07-08 2012-07-05 炎症性腸疾患の経口治療 Active JP6219277B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11173351 2011-07-08
EP11173351.5 2011-07-08
US201161506437P 2011-07-11 2011-07-11
US61/506,437 2011-07-11
PCT/EP2012/063137 WO2013007596A2 (en) 2011-07-08 2012-07-05 Oral treatment of inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017008251A Division JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Publications (3)

Publication Number Publication Date
JP2014523906A JP2014523906A (ja) 2014-09-18
JP2014523906A5 true JP2014523906A5 (enExample) 2015-08-20
JP6219277B2 JP6219277B2 (ja) 2017-10-25

Family

ID=47506622

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014519502A Active JP6219277B2 (ja) 2011-07-08 2012-07-05 炎症性腸疾患の経口治療
JP2017008251A Active JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017008251A Active JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Country Status (5)

Country Link
US (3) US9217021B2 (enExample)
EP (1) EP2729159B1 (enExample)
JP (2) JP6219277B2 (enExample)
ES (1) ES2637286T3 (enExample)
WO (1) WO2013007596A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172709A1 (en) 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
KR101590452B1 (ko) 2015-05-20 2016-02-02 중앙대학교 산학협력단 펩타이드 defb124를 유효성분으로 포함하는 면역증강 및 암 예방 또는 치료용 약학적 조성물
US20170035845A1 (en) * 2015-08-07 2017-02-09 The Regents Of The University Of California Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression
BR112018015170A2 (pt) * 2016-01-26 2018-12-18 Defensin Therapeutics Aps métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1.
CN109414474B (zh) * 2016-04-29 2024-07-02 诺维信公司 肝脏、胆道和胰腺障碍的治疗
JP7129912B2 (ja) * 2016-12-07 2022-09-02 株式会社ステリック再生医科学研究所 慢性疾患の治療及び予防用医薬組成物
MX2019006848A (es) 2016-12-13 2019-10-07 Defensin Therapeutics Aps Metodos para tratar condiciones inflamatorias de los pulmones.
MX2020004863A (es) * 2017-11-10 2020-10-14 Defensin Therapeutics Aps Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro.
PL3713590T3 (pl) * 2017-11-24 2025-09-15 Defensin Therapeutics Aps Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN113164390A (zh) * 2018-10-09 2021-07-23 达特·特兰 用于增强阳离子大环肽的全身递送能力、耐受性和效力的组合物和方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE19824484A1 (de) * 1998-06-02 1999-12-09 Bayer Ag Festkörperreiche Polyurethandispersionen mit hoher Applikationssicherheit
DE19957043A1 (de) 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
NZ540506A (en) 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US8895062B2 (en) 2006-01-24 2014-11-25 University Of Maryland, Baltimore Surface-layer protein coated microspheres and uses thereof
KR20100071985A (ko) 2007-09-11 2010-06-29 몬도바이오테크 래보래토리즈 아게 치료제로서의 데펜신 펩티드의 용도
AP2011005537A0 (en) 2008-07-18 2011-02-28 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins.
SG172709A1 (en) 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
US8232248B2 (en) 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
DK2343292T3 (da) * 2008-09-10 2014-11-03 Asahi Glass Co Ltd Nyt prostaglandin 12-derivat
JP2011121887A (ja) * 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP4620169B1 (ja) * 2010-01-28 2011-01-26 株式会社三和化学研究所 有機酸重合体を有効成分とするクローン病の予防又は治療剤
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide

Similar Documents

Publication Publication Date Title
JP2014523906A5 (enExample)
Liang et al. Therapeutic roles of polysaccharides from Dendrobium Officinaleon colitis and its underlying mechanisms
JP2012502113A5 (enExample)
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
US10653669B2 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
Wang et al. Targeting macrophage autophagy for inflammation resolution and tissue repair in inflammatory bowel disease
JP2020516615A5 (enExample)
JP2013544244A5 (enExample)
Li et al. Neglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity
JP2011520980A5 (enExample)
Sagnak et al. Predictive Value of Urinary Interleukin-8 Cutoff Point for Recurrences After Transurethral Resection Plus Induction Bacillus Calmette-Guérin Treatment in Non–Muscle-Invasive Bladder Tumors
Goh et al. Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine
EP3538132B1 (en) Rectal insulin for treatment of inflammatory bowel diseases
Khiong et al. Inhibition of NF-κB pathway as the therapeutic potential of red fruit (Pandanus conoideus Lam.) in the treatment of inflammatory bowel disease
CN102488699B (zh) 芍药苷在制备防治肺纤维化药物中的应用
WO2016150151A1 (zh) 青蒿琥酯在制备治疗中晚期脓毒症药物中的运用
Belhadjali et al. Sweet's syndrome associated with multiple myeloma
Gao et al. Tripterygium wilfordii polyglycosidium ameliorates pouchitis induced by dextran sulfate sodium in rats
Vaishnavi Management of Recurrent Apthous stomatitis-A Review
Hong et al. Annular leukocytoclastic vasculitis in a patient with ulcerative colitis
Fernandes et al. Paradoxical skin reaction with infliximab treatment
Zhai et al. Inflammatory Dermatosis in HIV/AIDS Patients
ES2541918T3 (es) Composición farmacéutica que combina un agente antiartrítico y un agente inhibidor de interleucina-1, que puede ser utilizado para controlar y tratar osteoartritis y enfermedades relacionadas
Plazyo et al. IFN-γ signaling in lichen planus
Basalamah et al. Stress-induced Oral Lichen Planus Immunopathogenesis and Potential Therapy: A Narrative Review